









































123. Bailey CJ, Turner RC (1996) Metformin. *N Engl J Med* 334: 574-579.
124. Inzucchi SE (2002) Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. *JAMA* 287: 360-372.
125. Mogensen CE (2003) Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. *J Intern Med* 254: 45-66.
126. Thurman JM, Schrier RW (2003) Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. *Am J Med* 114: 588-598.
127. The ACE Inhibitors in Diabetic Nephropathy Trialist Group (2001) Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A meta-analysis of individual patient data. *Ann Intern Med* 134: 370-379.
128. Andersen AR, Brochner-Mortensen J, Parving HH (2003) Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. *Diabetes Care* 26: 3296-3302.
129. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 106: 672-678.
130. American Diabetes Association (2004) Nephropathy in diabetes (Position Statement). *Diabetes Care* 27(Suppl 1): S79-S83.
131. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. *Lancet* 1: 1175-1179.
132. Rossing P, Hommel E, Smidt UM, Parving HH (1994) Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. *Diabetologia* 37: 511-516.
133. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, et al. (1995) Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study. *Ann Intern Med* 123: 754-762.
134. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med* 362: 1575-1585.
135. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, et al. (2000) ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure: VAL-K Study Group. *Kidney Int* 58: 2084-2092.
136. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, et al. (2000) Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. *BMJ* 321: 1440-1444.
137. Jacobsen P, Rossing K, Parving HH (2004) Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. *Curr Opin Nephrol Hypertens* 13: 319-324.
138. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, et al. (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomized controlled trial. *Lancet* 361: 117-124.
139. Bakris GL (2001) A practical approach to achieving recommended blood pressure goals in diabetic patients. *Arch Intern Med* 161: 2661-2667.
140. Working Party of the International Diabetes Federation (European Region) (2003) Hypertension in people with type 2 diabetes: Knowledge-based diabetes-specific guidelines. *Diabet Med* 20: 972-987.
141. Gross JL, Zelmanovitz T, Moulin CC, De Mello V, Perassolo M, et al. (2002) Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: A randomized crossover trial. *Diabetes Care* 25: 645-651.
142. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis. *Ann Intern Med* 124: 627-632.
143. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH (2002) Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. *Kidney Int* 62: 220-228.
144. Collins R, Armitage J, Parish S, Sleight P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. *Lancet* 361: 2005-2016.
145. Kawanami D, Matoba K, Utsunomiya K (2016) Dyslipidemia in diabetic nephropathy. *Ren Replace Ther* 2: 16.
146. Sinclair SH, DelVecchio C, Levin A (2003) Treatment of anemia in the diabetic patient with retinopathy and kidney disease. *Am J Ophthalmol* 135: 740-743.

147. Gaede P, Hansen HP, Parving HH, Pedersen O (2003) Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. *Nephrol Dial Transplant* 18: 539-542.
148. Hansen HP, Gaede PH, Jensen BR, Parving HH (2000) Lack of impact of low-dose acetylsalicylic acid on kidney function in type 1 diabetic patients with microalbuminuria. *Diabetes Care* 23: 1742-1745.
149. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, et al. (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): Its relation to metabolic control. *Thromb Res* 113: 101-113.
150. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 348: 383-393.
151. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high dose thiamine and benfotiamine. *Diabetes* 52: 2110-2120.
152. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, et al. (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. *FASEB J* 17: 1762-1764.
153. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, et al. (2003) Protein kinase C inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. *Diabetes* 52: 512-518.
154. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, et al. (2000) Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. *J Am Soc Nephrol* 11: 2324-2336.
155. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlova M, et al. (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. *J Am Soc Nephrol* 13: 1615-1625.
156. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, et al. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am J Nephrol* 24: 32-40.